RxDoctor Payments Data

Vitaliy Koss, MD

Neurology · Allentown, PANPI 1205149424

Payments from drug & device makers

$187,638in general payments, 2019–2025

Across 206 payments — averaging $910.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$66K
  • Amgen$52K
  • Teva Pharmaceuticals USA, Inc.$27K
  • Biohaven Pharmaceuticals, Inc.$18K
  • Biohaven Pharmaceutical Holding Company Ltd.$15K
  • Axsome Therapeutics, Inc.$7K
  • plus $3K from 4 others

What the payments were for

  • Consulting fees$2,9002%
  • Speaking & faculty fees$169,58790%
  • Travel & lodging$5,4603%
  • Food & beverage$9,6055%
  • Education$860%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)68$66,012
Amgen54$51,943
Teva Pharmaceuticals USA, Inc.30$27,116
Biohaven Pharmaceuticals, Inc.20$17,709
Biohaven Pharmaceutical Holding Company Ltd.14$15,018
Axsome Therapeutics, Inc.3$6,738
Pfizer2$1,750
Lundbeck LLC13$1,126
Promius Pharma LLC1$125
Impel Pharmaceuticals Inc.1$100

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$187,638 in reported general payments places this provider in the 90th percentile of 941 neurology providers in Pennsylvania.

See all neurology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$36,560
Medicare patients
170
Services billed
3,937

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant104$158,324
Nurtec OdtRimegepant Sulfate101$139,853
Aimovig AutoinjectorErenumab-Aooe109$109,901
Ajovy AutoinjectorFremanezumab-Vfrm57$52,540
QuliptaAtogepant40$45,895
BotoxOnabotulinumtoxina34$43,114
Emgality PenGalcanezumab-Gnlm20$16,904
Sumatriptan Succinate131$10,407
Sumatriptan13$3,382
Zolmitriptan22$2,750
Topiramate101$1,319
Gabapentin80$1,279
Lacosamide11$1,257
Carbamazepine ErCarbamazepine27$1,242
RizatriptanRizatriptan Benzoate73$1,081

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta, Botox$66,012$247,332178 claims
PfizerNurtec Odt$1,750$139,853101 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 941 neurology providers in Pennsylvania.

Other neurology in Allentown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →